Published in J Dermatol on October 01, 2016
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials (2007) 1.85
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist (2012) 1.01
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol (2012) 0.96
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol (2010) 0.91
Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther (2012) 0.87
Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly. J Eur Acad Dermatol Venereol (2012) 0.80
Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma. Nat Rev Clin Oncol (2015) 0.79
Notch down-regulation in regenerated epidermis contributes to enhanced expression of interleukin-36α and suppression of keratinocyte differentiation during wound healing. J Dermatol Sci (2015) 0.78
5-Hydroxymethylcytosine as a putative marker for erosive adenomatosis of the nipple. J Dermatol (2015) 0.75
Late Onset of Acute Urticaria after Bee Stings. Case Rep Dermatol (2016) 0.75
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma. J Dermatol (2020) 0.75
[Squamous cell carcinoma: new neoplasm staging system by UICC and AJCC (2009)]. Gan To Kagaku Ryoho (2011) 0.75
Water-based correction fluid is a useful skin marker for determination of the tumor margin of basal cell carcinoma under high-frequency ultrasound. J Dermatol (2016) 0.75
Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. J Dermatol (2015) 0.75
Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash. J Dermatol Sci (2015) 0.75
Eccrine porocarcinoma shares dermoscopic characteristics with eccrine poroma: A report of three cases and review of the published work. J Dermatol (2015) 0.75